CagriSema Data and Commercial Headwinds Converge for Novo Nordisk in Critical June Week

Novo Nordisk faces pivotal week at ADA with CagriSema data, but CVS formulary shift erodes Wegovy's edge; buyback ongoing.

Novo Nordisk enters a pivotal stretch this week, with the American Diabetes Association’s annual meeting in New Orleans presenting what many on the Street see as the single most important catalyst for the stock in the first half of 2026. Shares have lost more than 40% over the past twelve months, and the company is carrying the weight of both pipeline expectations and a deteriorating commercial position in its largest market.

The ADA conference runs from 5 to 8 June, with Novo Nordisk presenting around 40 abstracts from its cardiometabolic portfolio. Investor attention will be laser-focused on two sets of data: the phase 3 results of the REIMAGINE programme for CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide in type 2 diabetes, and phase 2b findings for Zenagamtid (formerly Amycretin), a dual GLP-1/amylin injectable. On 7 June, management will host an R&D investor day via webcast beginning at 18:30 CDT, where they are expected to lay out clinical outcomes and a regulatory roadmap for CagriSema. The FDA decision on that candidate is pencilled in for the fourth quarter of 2026.

The timing could hardly be more loaded. Even as the company heads to New Orleans with a promising pipeline story, it is contending with a structural shift in US pharmacy-benefit dynamics that undermines the commercial exclusivity Wegovy once enjoyed. CVS Caremark has elevated Eli Lilly’s Zepbound and the oral agent Foundayo to the same preferred formulary tier as Wegovy. Foundayo was listed on 1 June, and Zepbound follows on 1 October. The move erases the competitive edge Novo Nordisk held through 2025 and forces the company to rely more heavily on clinical differentiation and physician preference to hold market share.

A partial offset comes from a new Medicare access channel. Starting 1 July 2026, eligible Medicare beneficiaries with obesity will be able to obtain Wegovy for a monthly copay of $50 under the so-called Medicare GLP-1 Bridge Programme, which runs through the end of 2027. The Centers for Medicare & Medicaid Services negotiated a net price of around $245 per monthly supply directly with Novo Nordisk and Eli Lilly. The programme fills a gap in Part D coverage for weight-management drugs, but the CVS Caremark decision will blunt its impact by ensuring that competing products are available on equal footing in the commercial market.

Behind the scenes, Novo Nordisk is deploying a sizeable share buyback as a financial anchor. The overall programme authorises up to 15 billion Danish kroner and runs until February 2027. Within that envelope, the current tranche is capped at roughly 11.2 billion kroner. Since early February, the company has repurchased about 17.9 million B-shares at an average price of 263.47 kroner, for a total outlay of just under 4.7 billion kroner. The pace has been steady: in the final week of May, Novo Nordisk bought around 210,000 B-shares daily, with the 29 May purchase priced at an average of 293.42 kroner, or 61.6 million kroner for the day.

Despite those buybacks, the stock closed recently at €36.97, roughly 47% below its 52-week high of €70.13. The relative strength index sits at 71.6, indicating mild overbought conditions after a rally from the March 2026 trough of €30.48. The current price earnings multiple hovers around 10.3, a sharp compression from the lofty valuations of 2024 that reflects mounting competition in the GLP 1 obesity space. The dividend for fiscal 2025 came in at 11.70 kroner per share.

Investors now face a week where two opposing forces — a potentially transformative data readout and a commercial landscape that is becoming more contested by the month — will collide. The clinical results from New Orleans, coupled with the clarity offered on the CagriSema regulatory path, are likely to set the tone for the stock well beyond June.